David Endicott: Yes, Larry, you’re not wrong. The North American market this last year was relatively subdued but everybody has kind of they wrapped around the COVID is one of the ways you got to keep looking at it is what’s the natural growth rate? And then what is it on ’19? Because I think usually a 2-year number on ’21, skip over ’21 has been a pretty good idea. What we’ve seen on this year was the Surgical business on a full year basis, the market was roughly around 4% the Vision Care business, the contact lens care market was roughly around kind of 3%, 4%. Those are very historical numbers. A little softer on Vision Care than we would have expected probably for the full year — sorry, for that was the fourth quarter but the full year was also on the U.S. was 4%.
So directionally, I think we feel like — in the fourth quarter, we saw a little bit of softness with unit growth, where most of the 4% was in Vision Care was made up of price and mix. So yes, we’re being a little careful but I think the fact of under is we’re lucky we’re in resilient markets directionally. And I think what we’re talking about are relatives here. So we think cataracts don’t go away. We think eye surgery and eye disorders don’t go away and that directionally, we’re going to see historical growth rates in the kind of we’ve always said kind of 4% to 5% range is the market depending on which 1 we’re talking about. So a little bit soft to that is what we’re calling it, principally because the Vision Care market, I think, has the potential as we look at ’09 and what happened there, to come off a little bit.
So it came off of a high of, I think, 8% in ’08, went down to maybe 3%-ish in — still growing but in the ’09 frame. And a lot of that was really exactly the same. It was a slowdown in units, so under new starts. We don’t see that internationally yet but we’re wrapping around soft numbers because of COVID. So I think given the, I would say, the uncertainty of the market, we felt it was best to plan for at least a softness in the market. If we’re wrong, obviously, we’ll lean into it. But like I said, we’re over-indexed in the high-growth areas. So I feel like we got a pretty good plan and we’re prepared to do well.
Tim Stonesifer: Yes. And then as far as the cadence, Larry, revenue, I think it’s going to be broadly in line with historical trends. So I go back to ’21, ’22, you can probably go back to ’19, I wouldn’t look at ’20. And as we’ve seen historically, Q2 and Q4 are typically higher than Q1 and Q3 from a revenue perspective. If you think about allergy season, that’s predominantly in Q2, surprised revenues up. And then when you get to Q4, hospitals are managing their capital budgets. Consumers are managing their co-pays by the end of the year. So we typically see a little bit of a renew lift in Q4 as well. And then while we’re on cadence, just from a P&L perspective, if you look at R&D, that will be a gradual progression throughout the year as we’ve seen in the past.
SG&A, I’d just remind folks that Q2 is a heavy spend for us as we get advertising and promotions, back-to-school programs, things like that. So I take a look at those historical trends because there’s a big jump from Q1 to Q2. And then interest expense, I would just level load the interest expense.
Larry Biegelsen: The inorganic contribution, Tim, about 2% in ’23?
Tim Stonesifer: Yes, that’s about right.
Operator: Our next question comes from the line of Daniel Buchta with ZKB.
